Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of SLCO1B1 (rs2306283) polymorphism on personalized atorvastatin dosing in a genetically distinct South Asian cohort.

BMC pharmacology & toxicology - 12 Nov 2025

Farooq Tayaba, Naeem Uzma, Siddique Afifa, Kausar Samia, Waheed Akbar, Mumal Sidra

Abstract excerpt

PURPOSE: Dyslipidemia is a prevalent condition in the Pakistani population, significantly contributing to coronary heart disease (CHD). Atorvastatin, a widely used hypolipidemic drug, exhibits variable efficacy and safety influenced by genetic factors. This study aimed to assess the impact of SLCO1B1 rs2306283 (A > G) polymorphism on the efficacy and safety profile of atorvastatin in the Pakistani population....

Topics

Join the communities discussing this publication.

Atorvastatin
Dyslipidemias
Gene Frequency
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Liver-Specific Organic Anion Transporter 1

Muscular Diseases

South Asian People

Source

Open in PubMed Open full text

Identifiers

PMID: 41225666
DOI: 10.1186/s40360-025-01022-x
PMCID: PMC12613677

Genes

SLCO1B1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of SLCO1B1 (rs2306283) polymorphism on personalized atorvastatin dosing in a genetically distinct South Asian cohort.PMID 41225666Read ↗

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.Semantic proximity Read ↗

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.Semantic proximity Read ↗

Statin-induced myopathy SLCO1B1 521T > C is associated with prediabetes, high body mass index and normal lipid profile in Emirati population.Semantic proximity Read ↗

Genetic Polymorphisms in Drug Transporter Genes (ABCB1, OATP1B1) and Their Impact on Statin Pharmacokinetics and Myopathy RiskSemantic proximity Read ↗

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.Semantic proximity Read ↗

Impact of SLCO1B1 and ABCB1 variants on statin efficacy and toxicity in a Tunisian population.Semantic proximity Read ↗

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin BioavailabilitySemantic proximity Read ↗

Genetic Determinants of Statin-induced Myopathy: A Network Meta-analysis of Observational Studies.Semantic proximity Read ↗

Pharmacogenomic insights into treatment and management of statin-induced myopathySemantic proximity Read ↗

Impact of Pharmacokinetic Gene Polymorphisms on Statin-Induced Myotoxicity in Thai Patients Treated With Simvastatin.Semantic proximity Read ↗

The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence.Semantic proximity Read ↗

The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.